Vestcor Inc Acquires 1,990 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Vestcor Inc grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 13.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,896 shares of the company’s stock after acquiring an additional 1,990 shares during the period. Vestcor Inc’s holdings in Teva Pharmaceutical Industries were worth $372,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Smithfield Trust Co lifted its stake in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $66,000. IFP Advisors Inc lifted its position in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after buying an additional 1,960 shares in the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at approximately $104,000. 54.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on TEVA. Bank of America decreased their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Friday, March 7th. Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Finally, UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $16.74 on Tuesday. The company has a market capitalization of $18.97 billion, a P/E ratio of -11.54, a PEG ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The business has a 50 day moving average price of $18.19 and a 200 day moving average price of $18.28.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.